For what reasons does insulin remain a foundational therapy for managing patients with T2D? And why does the addition of a GLP-1 RA potentially augment the utility of insulin-based management?

For what reasons does insulin remain a foundational therapy for managing patients with T2D? And why does the addition of a GLP-1 RA potentially augment the utility of insulin-based management?

For what reasons does insulin remain a foundational therapy for managing patients with T2D? And why does the addition of a GLP-1 RA potentially augment the utility of insulin-based management?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Hertzel Gerstein, MD

Hertzel Gerstein, MD

Professor of Medicine
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada